Beam Therapeutics Inc. 8-K

What Happened

• Beam Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished the related press release on May 7, 2026 in a Form 8-K (Item 2.02). The company’s press release is included as Exhibit 99.1 to the filing. The 8-K was signed by CEO John Evans.

Key Details

• Filing date: May 7, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Item disclosed: 2.02 Results of Operations and Financial Condition — press release of quarterly results furnished as Exhibit 99.1.
• Administrative exhibit: Exhibit 104 (Inline XBRL cover page data) was also included with the filing.

Why It Matters

• This 8-K makes Beam’s quarterly earnings and related financial information public; investors should read the furnished press release for specific earnings figures (revenue, net income/loss), cash position, and any commentary on pipeline or guidance. Quarterly results and management commentary can affect investor views on the company’s financial health and near-term outlook.